NYSE:BMY - Bristol-Myers Squibb Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$52.34 +0.10 (+0.19 %)
(As of 05/23/2018 06:51 AM ET)
Previous Close$52.24
Today's Range$52.20 - $52.82
52-Week Range$49.96 - $70.05
Volume3.75 million shs
Average Volume9.13 million shs
Market Capitalization$85.39 billion
P/E Ratio17.39
Dividend Yield3.06%
Beta0.99

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb logoBristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:BMY
CUSIP11012210
Phone212-546-4000

Debt

Debt-to-Equity Ratio0.45
Current Ratio1.52
Quick Ratio1.39

Price-To-Earnings

Trailing P/E Ratio17.39
Forward P/E Ratio15.35
P/E Growth1.31

Sales & Book Value

Annual Sales$20.78 billion
Price / Sales4.12
Cash Flow$3.5246 per share
Price / Cash14.85
Book Value$7.90 per share
Price / Book6.63

Profitability

EPS (Most Recent Fiscal Year)$3.01
Net Income$1.01 billion
Net Margins4.37%
Return on Equity37.56%
Return on Assets15.27%

Miscellaneous

Employees23,700
Outstanding Shares1,634,540,000

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, March 1st. Stockholders of record on Friday, April 6th will be given a dividend of $0.40 per share on Tuesday, May 1st. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend is Thursday, April 5th. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) released its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.09. The biopharmaceutical company earned $5.19 billion during the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The company's revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.84 EPS. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $3.35-3.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.26.

What price target have analysts set for BMY?

19 equities research analysts have issued 1-year price targets for Bristol-Myers Squibb's shares. Their predictions range from $47.00 to $78.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $62.6519 in the next twelve months. View Analyst Ratings for Bristol-Myers Squibb.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 14,317,338 shares, an increase of 28.5% from the March 30th total of 11,139,095 shares. Based on an average daily trading volume, of 7,952,211 shares, the days-to-cover ratio is currently 1.8 days. Currently, 0.9% of the shares of the stock are short sold.

Who are some of Bristol-Myers Squibb's key competitors?

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 53)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 58)
  • Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 57)
  • Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
  • Mr. Murdo Gordon, Exec. VP & Chief Commercial Officer (Age 51)

Has Bristol-Myers Squibb been receiving favorable news coverage?

Headlines about BMY stock have been trending somewhat positive on Wednesday, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of 0.11 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.92 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.39%), Northern Trust Corp (1.40%), Loomis Sayles & Co. L P (0.82%), Legal & General Group Plc (0.49%), Massachusetts Financial Services Co. MA (0.41%) and Schwab Charles Investment Management Inc. (0.37%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Northern Trust Corp, Swiss National Bank, Prudential Financial Inc., OppenheimerFunds Inc., Manning & Napier Group LLC, Legal & General Group Plc and State of Tennessee Treasury Department. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was acquired by a variety of institutional investors in the last quarter, including Argent Capital Management LLC, Rock Springs Capital Management LP, Massachusetts Financial Services Co. MA, DekaBank Deutsche Girozentrale, Rockefeller Capital Management L.P., Mackay Shields LLC, Summit Trail Advisors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $52.34.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $85.39 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK NY, 10154. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb (BMY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  729 (Vote Outperform)
Underperform Votes:  705 (Vote Underperform)
Total Votes:  1,434
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bristol-Myers Squibb (NYSE:BMY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Bristol-Myers Squibb in the last 12 months. Their average twelve-month price target is $62.6519, suggesting that the stock has a possible upside of 19.70%. The high price target for BMY is $78.00 and the low price target for BMY is $47.00. There are currently 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.372.402.472.47
Ratings Breakdown: 0 Sell Rating(s)
12 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $62.6519$64.2144$67.0714$64.50
Price Target Upside: 19.70% upside24.42% upside2.77% downside7.61% upside

Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History

Price Target History for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2018UBSDowngradeBuy ➝ Neutral$57.00LowView Rating Details
4/27/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$65.00 ➝ $55.00LowView Rating Details
4/27/2018BMO Capital MarketsUpgradeUnderperform ➝ Market PerformLowView Rating Details
4/26/2018Credit Suisse GroupSet Price TargetHold$58.00LowView Rating Details
4/20/2018CowenReiterated RatingHold$60.00LowView Rating Details
4/17/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$68.00 ➝ $61.00LowView Rating Details
4/17/2018William BlairReiterated RatingOutperformHighView Rating Details
4/17/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$54.08 ➝ $58.00HighView Rating Details
4/13/2018Jefferies GroupReiterated RatingHold$66.00LowView Rating Details
3/21/2018ArgusReiterated RatingBuy$75.00 ➝ $66.43LowView Rating Details
3/20/2018JPMorgan ChaseSet Price TargetOverweight ➝ Overweight$70.00 ➝ $75.00LowView Rating Details
2/28/2018DZ BankDowngradeBuy ➝ HoldHighView Rating Details
2/16/2018CitigroupSet Price TargetBuy$78.00LowView Rating Details
2/6/2018Leerink SwannBoost Price TargetOutperform ➝ Positive$71.00 ➝ $76.00MediumView Rating Details
10/30/2017SunTrust BanksUpgradeHold ➝ BuyN/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$60.00N/AView Rating Details
9/12/2017Hilliard LyonsDowngradeLong-term Buy ➝ Neutral$65.00LowView Rating Details
9/7/2017Goldman SachsReiterated RatingBuy$62.00 ➝ $65.00LowView Rating Details
7/17/2017Deutsche BankSet Price TargetHold$54.00 ➝ $55.00LowView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy ➝ Hold$80.00 ➝ $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 ➝ $65.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Bristol-Myers Squibb (NYSE:BMY) Earnings History and Estimates Chart

Earnings by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Earnings Estimates

2018 EPS Consensus Estimate: $3.26
2019 EPS Consensus Estimate: $3.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.74$0.88$0.83
Q2 20183$0.76$0.88$0.83
Q3 20183$0.77$0.86$0.82
Q4 20183$0.76$0.84$0.79
Q1 20191$0.83$0.83$0.83
Q2 20191$0.85$0.85$0.85
Q3 20191$0.88$0.88$0.88
Q4 20191$0.90$0.90$0.90

Bristol-Myers Squibb (NYSE BMY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$0.86N/AView Earnings Details
4/26/2018Q1 2018$0.85$0.94$5.2509 billion$5.1930 billionViewN/AView Earnings Details
2/5/2018Q4 2017$0.67$0.68$5.3479 billion$5.4490 billionViewListenView Earnings Details
10/26/2017Q3 2017$0.77$0.75$5.1957 billion$5.2540 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.0876 billion$5.1440 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.7485 billion$4.9290 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bristol-Myers Squibb (NYSE:BMY) Dividend Information

Bristol-Myers Squibb pays an annual dividend of $1.60 per share, with a dividend yield of 3.06%. BMY's most recent quarterly dividend payment was Tuesday, May 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 2.70% each year. Bristol-Myers Squibb pays out 53.16% of its earnings out as a dividend.
Most Recent Dividend:5/1/2018
Annual Dividend:$1.60
Dividend Yield:3.06%
Dividend Growth:2.70% (3 Year Average)
Payout Ratio(s):53.16% (Trailing 12 Months of Earnings)
46.92% (Based on This Year's Estimates)
44.08% (Based on Next Year's Estimates)
45.40% (Based on Cash Flow)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/1/2018quarterly$0.402.43568275232151%4/5/20184/6/20185/1/2018
12/7/2017quarterly$0.402.56%1/4/20181/5/20182/1/2018
9/13/2017quarterly$0.392.49%10/5/201710/6/201711/1/2017
6/13/2017quarterly$0.392.86%7/5/20177/7/20178/1/2017
3/2/2017quarterly$0.392.72%4/5/20174/7/20175/1/2017
12/8/2016quarterly$0.392.73%1/4/20171/6/20172/1/2017
8/3/2016quarterly$0.382.02%10/5/201610/7/201611/1/2016
6/7/2016quarterly$0.382.07%6/29/20167/1/20168/1/2016
3/3/2016quarterly$0.382.35%3/30/20164/1/20165/2/2016
12/8/2015quarterly$0.382.22%12/30/20151/4/20162/1/2016
9/17/2015quarterly$0.372.3%9/30/201510/2/201511/2/2015
6/16/2015quarterly$0.372.23%7/1/20157/6/20158/3/2015
3/2/2015quarterly$0.372.39%4/1/20154/6/20155/1/2015
12/9/2014quarterly$0.372.5%12/30/20141/2/20152/2/2015
9/16/2014quarterly$0.362.83%10/1/201410/3/201411/3/2014
6/17/2014quarterly$0.363%7/1/20147/3/20148/1/2014
3/3/2014quarterly$0.362.55%4/2/20144/4/20145/1/2014
12/19/2013quarterly$0.362.7%12/31/20131/3/20142/3/2014
9/17/2013quarterly$0.352.95%10/2/201310/4/201311/1/2013
6/19/2013quarterly$0.353.14%7/2/20137/5/20138/1/2013
3/7/2013quarterly$0.353.74%4/3/20134/5/20135/1/2013
12/4/2012quarterly$0.351/4/20132/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.12%
Institutional Ownership Percentage: 71.29%
Insider Trading History for Bristol-Myers Squibb (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/30/2018Dinesh C PaliwalDirectorBuy4,770$52.40$249,948.008,027View SEC Filing  
12/15/2017Theodore R Samuels IIDirectorBuy4,000$62.30$249,200.0022,000View SEC Filing  
12/12/2017Thomas J Jr. LynchEVPSell5,300$63.24$335,172.009,251View SEC Filing  
12/4/2017Sandra LeungEVPSell156,582$63.37$9,922,601.34584,373View SEC Filing  
9/6/2017Joseph C CaldarellaSVPSell9,340$60.00$560,400.0046,297View SEC Filing  
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.0018,000View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00952,571View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00986,112View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00986,112View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.0021,483View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.8455,637View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10488,063View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.0012,000View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00334,499View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00364,999View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00380,099View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00403,094View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.8055,011View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79184,694View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.9355,238View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16444,507View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00425,194View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14132,263View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94128,463View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60536,794View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.1021,971View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00453,094View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00453,094View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00381,254View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.002,500View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.6846,322View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.2076,738View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64309,547View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00392,854View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00310,424View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00310,424View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00332,852View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00456,052View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00524,252View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00546,874View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.4068,965View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00630,783View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.198,861View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00273,393View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.1214,696View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.7249,753View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.4832,740View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00207,237View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.0577,303View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20195,855View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50500,487View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.9059,355View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00373,393View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bristol-Myers Squibb (NYSE BMY) News Headlines

Source:
DateHeadline
Bristol-Myers Squibb (BMY) Rating Lowered to Hold at UBSBristol-Myers Squibb (BMY) Rating Lowered to Hold at UBS
www.americanbankingnews.com - May 21 at 11:05 AM
$5.40 Billion in Sales Expected for Bristol-Myers Squibb Co (BMY) This Quarter$5.40 Billion in Sales Expected for Bristol-Myers Squibb Co (BMY) This Quarter
www.americanbankingnews.com - May 21 at 3:04 AM
3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Ataras Immunotherapy Data3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara's Immunotherapy Data
seekingalpha.com - May 20 at 9:00 AM
$0.86 EPS Expected for Bristol-Myers Squibb (BMY) This Quarter$0.86 EPS Expected for Bristol-Myers Squibb (BMY) This Quarter
www.americanbankingnews.com - May 19 at 1:24 PM
Global Bipolar Disorder Market Growth Opportunities: Sumitomo Dainippon Pharma Co., Allergan, Bristol-Myers Squibb CompanyGlobal Bipolar Disorder Market Growth Opportunities: Sumitomo Dainippon Pharma Co., Allergan, Bristol-Myers Squibb Company
www.marketwatch.com - May 18 at 9:46 AM
Bristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCOBristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO
www.streetinsider.com - May 17 at 5:14 PM
Immunomedics Announces Positive Phase 2 ResultsImmunomedics Announces Positive Phase 2 Results
finance.yahoo.com - May 17 at 5:14 PM
Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018
finance.yahoo.com - May 16 at 5:21 PM
Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare ConferenceBristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference
finance.yahoo.com - May 15 at 8:42 AM
Exploring Bristol-Myers Squibb’s Financial PerformanceExploring Bristol-Myers Squibb’s Financial Performance
finance.yahoo.com - May 15 at 8:42 AM
How Bristol-Myers Squibb’s Key Products Performed in 1Q18How Bristol-Myers Squibb’s Key Products Performed in 1Q18
finance.yahoo.com - May 14 at 5:13 PM
What’s Bristol-Myers Squibb’s Business Strategy?What’s Bristol-Myers Squibb’s Business Strategy?
finance.yahoo.com - May 14 at 5:13 PM
Bristol-Myers Squibb (BMY) Receives Average Rating of "Hold" from AnalystsBristol-Myers Squibb (BMY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 13 at 5:31 PM
Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) Drug Overview 2017/18-2026: An Orally Available Factor Xa Inhibitor Indicated for the Prevention of Venous Thromboembolsim ...Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) Drug Overview 2017/18-2026: An Orally Available Factor Xa Inhibitor Indicated for the Prevention of Venous Thromboembolsim ...
www.businesswire.com - May 11 at 5:35 PM
Label Expansion May Boost Keytruda’s Revenue Prospects in 2018Label Expansion May Boost Keytruda’s Revenue Prospects in 2018
finance.yahoo.com - May 11 at 9:31 AM
Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer OutcomesYoung Lung Cancer Investigators Awarded $200K to Improve Lung Cancer Outcomes
www.prnewswire.com - May 11 at 7:30 AM
How Merck’s Animal Health Segment Did in 1Q18How Merck’s Animal Health Segment Did in 1Q18
finance.yahoo.com - May 10 at 8:45 AM
Why Bristol-Myers Squibb Stock Crashed in AprilWhy Bristol-Myers Squibb Stock Crashed in April
www.fool.com - May 9 at 12:58 PM
Q4 2018 EPS Estimates for Bristol-Myers Squibb Raised by SunTrust Banks (BMY)Q4 2018 EPS Estimates for Bristol-Myers Squibb Raised by SunTrust Banks (BMY)
www.americanbankingnews.com - May 9 at 9:06 AM
See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
finance.yahoo.com - May 9 at 8:40 AM
New 52-Week Low Could Prompt More Insider Buying At BMYNew 52-Week Low Could Prompt More Insider Buying At BMY
www.nasdaq.com - May 8 at 5:19 PM
Q2 2018 EPS Estimates for Bristol-Myers Squibb Lifted by Analyst (BMY)Q2 2018 EPS Estimates for Bristol-Myers Squibb Lifted by Analyst (BMY)
www.americanbankingnews.com - May 8 at 5:56 AM
Bristol-Myers Squibb Co. (BMY) PT Lowered to $69 at SunTrust Robinson HumphreyBristol-Myers Squibb Co. (BMY) PT Lowered to $69 at SunTrust Robinson Humphrey
www.streetinsider.com - May 7 at 9:31 AM
Allergan’s International Business in 1Q18Allergan’s International Business in 1Q18
finance.yahoo.com - May 7 at 9:31 AM
As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soarsAs emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soars
finance.yahoo.com - May 5 at 8:39 AM
BRIEF-EMA Validates Bristol-Myers Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment ...BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment ...
www.reuters.com - May 4 at 8:29 AM
Bristol-Myers Squibb (BMY) Says EMA Validated its Type II Variation Application for Opdivo Plus Yervoy Combination ...Bristol-Myers Squibb (BMY) Says EMA Validated its Type II Variation Application for Opdivo Plus Yervoy Combination ...
www.streetinsider.com - May 4 at 8:29 AM
BRIEF-Bristol-Myers Squibb Elects Each Of Companys 12 Nominees To Serve As DirectorsBRIEF-Bristol-Myers Squibb Elects Each Of Company's 12 Nominees To Serve As Directors
www.reuters.com - May 4 at 8:29 AM
Bristol-Myers Squibb (BMY) Expected to Post Quarterly Sales of $5.38 BillionBristol-Myers Squibb (BMY) Expected to Post Quarterly Sales of $5.38 Billion
www.americanbankingnews.com - May 4 at 4:40 AM
Bristol-Myers Squibb (BMY) Downgraded to "Sell" at ValuEngineBristol-Myers Squibb (BMY) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - May 3 at 10:32 PM
Bristol-Myers to team up with Flatiron Health for an additional three yearsBristol-Myers to team up with Flatiron Health for an additional three years
seekingalpha.com - May 3 at 8:39 AM
Global Polycystic Ovarian Syndrome Treatment Market Competitive landscape: Bristol-Myers Squibb CompanyGlobal Polycystic Ovarian Syndrome Treatment Market Competitive landscape: Bristol-Myers Squibb Company
www.marketwatch.com - May 3 at 8:39 AM
BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year AgreementBRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement
www.reuters.com - May 2 at 5:13 PM
Bristol-Myers Squibb (BMY), Flatiron Health Expand Collaboration with Three-Year AgreementBristol-Myers Squibb (BMY), Flatiron Health Expand Collaboration with Three-Year Agreement
www.streetinsider.com - May 2 at 5:13 PM
Comparing BMY’s and LLY’s ValuationComparing BMY’s and LLY’s Valuation
finance.yahoo.com - May 2 at 5:13 PM
The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and HondaThe Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda
finance.yahoo.com - May 2 at 5:13 PM
Dinesh C. Paliwal Buys 4,770 Shares of Bristol-Myers Squibb (BMY) StockDinesh C. Paliwal Buys 4,770 Shares of Bristol-Myers Squibb (BMY) Stock
www.americanbankingnews.com - May 2 at 4:38 PM
Eli Lilly Expected to Report a Modest Rise in Revenues in 2018Eli Lilly Expected to Report a Modest Rise in Revenues in 2018
finance.yahoo.com - May 2 at 8:26 AM
$0.85 Earnings Per Share Expected for Bristol-Myers Squibb (BMY) This Quarter$0.85 Earnings Per Share Expected for Bristol-Myers Squibb (BMY) This Quarter
www.americanbankingnews.com - May 2 at 1:22 AM
How Bristol-Myers Squibbs new Peninsula digs boost its battle to beat cancerHow Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
www.bizjournals.com - May 1 at 5:14 PM
Dow Jones' Merck Slides On Mixed First Quarter As Keytruda Sales PopDow Jones' Merck Slides On Mixed First Quarter As Keytruda Sales Pop
finance.yahoo.com - May 1 at 5:14 PM
How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancerHow Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
finance.yahoo.com - May 1 at 5:14 PM
Ramp Up In Opdivo And Eliquis Sales Bolsters Bristol-Myers Squibbs Q1 EarningsRamp Up In Opdivo And Eliquis Sales Bolsters Bristol-Myers Squibb's Q1 Earnings
www.forbes.com - April 30 at 4:10 PM
3 Things In Biotech, April 29: Bristol-Myers Widens, Ono Takes On Pheo, BrainStorms ALS Adventure Moves Forward3 Things In Biotech, April 29: Bristol-Myers Widens, Ono Takes On Pheo, BrainStorm's ALS Adventure Moves Forward
seekingalpha.com - April 30 at 9:52 AM
Q2 2018 Earnings Estimate for Bristol-Myers Squibb (BMY) Issued By William BlairQ2 2018 Earnings Estimate for Bristol-Myers Squibb (BMY) Issued By William Blair
www.americanbankingnews.com - April 30 at 2:14 AM
Bristol-Myers Squibb (BMY) Short Interest Up 28.5% in AprilBristol-Myers Squibb (BMY) Short Interest Up 28.5% in April
www.americanbankingnews.com - April 30 at 1:18 AM
BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral PositionBMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position
finance.yahoo.com - April 29 at 8:26 AM
Lupus Research Alliance and Lupus Therapeutics Collaborate with Bristol-Myers Squibb on a New Lupus TrialLupus Research Alliance and Lupus Therapeutics Collaborate with Bristol-Myers Squibb on a New Lupus Trial
www.prnewswire.com - April 28 at 5:13 PM
Bristol-Myers Squibb (BMY) Reports Clinical Trial Collaboration with Advantagene Inc.Bristol-Myers Squibb (BMY) Reports Clinical Trial Collaboration with Advantagene Inc.
www.streetinsider.com - April 28 at 5:13 PM
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo ImpressesBristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
finance.yahoo.com - April 27 at 5:10 PM

SEC Filings

Bristol-Myers Squibb (NYSE:BMY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bristol-Myers Squibb (NYSE BMY) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.